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Controlled Human Malaria Infection (CHMI) is the most practiced controlled human infection model
nowadays and there is an exponential increase in implementation of the model worldwide. During the
Controlled Human Infection Models Workshop in Leiden, one day was dedicated to the discussion of
the advances made and gaps in Controlled Human Malaria Infection (CHMI) trials. Factors contributing
to this impressive expansion in the number of CHMI trials have been related to the ability to perform
CHMI using injectable cryopreserved sporozoites (a product from Sanaria Inc. – PfSPZ Challenge), the
development of a transmission blocking CHMI model and the need to test more vaccine candidates par-
ticularly in the field of whole-sporozoite vaccine development. However, with an increasing number of
CHMI trials being undertaken, in an ever-growing number of trial sites, heterogeneity in trial design
may compromise universal interpretation of results and require an ongoing dialogue on the need and fea-
sibility of standardization. At the workshop, CHMI investigators convened to share their experiences in
CHMI trials and discuss the possibilities for future trials.1. Introduction
Since the first deliberate infection of volunteers with malaria as
a treatment for neurosyphilis in the 1920s [1,2], controlled human
malaria infections (CHMI) have been developed as a standardized
model to investigate malaria pathophysiology, immunology and
the efficacy of novel vaccines and drugs. With the exponential
expansion of CHMI trials worldwide and an estimated >3000 vol-
unteers being deliberately infected on five different continents to
date, CHMI have taken a central position in the development of
novel vaccines and medicine. Generally, CHMI testing novel vacci-
nes and drugs will be performed after the phase 1 safety trial for
the novel product has been completed. CHMI will then provide
the first data on efficacy of the product. The general design of CHMI
trials for evaluating novel vaccines or drugs is similar (Fig. 1). How-
ever, subtle differences in the way such trials are performed may
influence trial results and interpretation.In this report we present the different viewpoints on the use
and interpretation of these models which were discussed at the
Controlled Human Infection Models Workshop in Leiden.2. Keys to CHMI trial design: Inoculum and endpoints
Traditionally, malaria drug and vaccine developers target
different life cycle stages (pre-erythrocytic, blood- and sexual stage
parasites). In analogy to vaccine development, CHMI models were
developed to target specific life cycle stages. Exposure to mosquito
bites is the most mature and frequently used model, which
resembles the natural life cycle of malaria parasites in the human
host. Alternatively, volunteers can be injected with blood stage
parasites. The more recent availability of cryopreserved parasites
(PfSPZ Challenge, Sanaria Inc.) for intravenous inoculation has
changed the landscape for CHMI trials with sporozoites [3]
(Fig. 2). With regards to the trial endpoints, the advance of
molecular technology for fast and accurate parasite detection as
an alternative to traditional microscopy of blood smears, has diver-
sified the design of CHMI trials [4,5]. Benjamin Mordmüller
(University of Tübingen, Germany), Jona Walk (representing the
Fig. 1. Overall design of CHMI trials testing novel vaccines (A) or medicine (B). When testing vaccines, two groups of volunteers will be randomized, immunized with the
vaccine or (placebo) comparator and subsequently infected with malaria. Endpoint in such trials is blood stage parasitemia which may not occur (full protection) or be
reduced (partial protection). When testing novel antimalarial medicines, volunteers will be infected and subsequently randomized to receive novel medication or the
comparator drug. Endpoint in such trials is generally parasite clearance time in the blood.
Fig. 2. Illustration of the heterogeneity in CHMI trial design. Volunteers can be infected by mosquito bite (A), injection of sporozoites (B) or injection of blood stage parasites
(C). Subsequently, parasitemia in the blood can be measured by microscopy (thick smears) or by PCR. The detection threshold for these two techniques are 2 parasites per ul
and 20 parasites per ml respectively. p = parasites, ml = millilitre, ul = microliter.
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Netherlands), Jim Kublin (Seattle Malaria Clinical Trials Center,
USA) and Matt Laurens (University of Maryland, USA) discussed
the optimal design of CHMI including their infection procedures
and trial endpoints.
The panel discussion focussed around different infection tech-
niques using sporozoites: more natural mosquito bites versus the
more standardized direct venous inoculation. Inoculation of para-
sites by needle is clearly easier to standardize and can be used
across the world also in centres lacking an insectary. The direct
venous inoculation has shown to be the most efficient method ofinfection [5]. Other methods of administration (intradermal, subcu-
taneous, intramuscular) have been tried but were less efficient in
inducing parasitemia and clinical malaria [6–10]. The use of the
natural mosquito vector to deliver the controlled malaria infection
is thought to more closely resemble the field situation by some
researchers, as it does not circumvent the skin inoculation site.
The skin may be an important immunological site for both the
induction and the effector mechanism of immunity, but its rele-
vance in malaria is still under debate [11]. In any case, even in mos-
quito bite infections a portion of parasites are inoculated directly in
the blood stream. There are discussions on the requirement of five
M. Roestenberg et al. / Vaccine 35 (2017) 7065–7069 7067mosquito bites to achieve infection in all trial volunteers. This
might be ‘‘supra-natural” as five infectious bites almost never occur
simultaneously and without interruption during feeding in nature.
Because valid arguments for both techniques can be made, the
trial design should clearly be hypothesis-driven and tailored to
the specific trial objectives. A head-to-head comparison of mos-
quito bite versus needle infection may be needed to allow
researcher to make an informed choice when possible.
Traditionally, microscopy of thick blood smears is used as end-
point for CHMI trials. In exceptional circumstances, parasitemia can
be allowed to increase beyond the thick smear threshold based on
clinical criteria. The turnaround timeof sensitive PCRs for the diagno-
sis of Plasmodium falciparum (Pf) malaria has decreased to six hours
and is competing with traditional microscopy of thick smears as
the endpoint of CHMI. The sensitivity of PCR can be as low as 20 par-
asites permL of blood, compared tomicroscopy (2000 parasites per
mL) [4,12–14]. Therefore, PCR can diagnose malaria 2–4 days
(1–2 growth cycles) earlier than thick blood smear. This may
decrease the number of adverse events and improve the tolerability
of CHMI trials.Whereas the consumables for PCR aremore expensive,
it is less labour intensive when multiple samples are tested in one
run. In low-income settings, traditional microscopy is still often the
preferred option as it is cheaper, comparatively easy to implement
and does not require complicated technical infrastructure.3. Increasing diversity of CHMI: more species and more strains
Malaria parasites are known for their antigenic variation [15].
Most CHMI trials have been performed using either the
NF54/3D7 strain, derived from the Schiphol area. The 3D7 strain
has been obtained from NF54 by cloning. Because this strain has
been cultured for years, it may have diverged from field strains.
Particularly for vaccine testing, the strain used in CHMI trials
may be critical to the trial outcome because homology between
the vaccine antigen and the CHMI strain may lead to increased vac-
cine efficacy, which can be an overestimation as compared to the
field. This holds true for subunit vaccines as well as whole sporo-
zoite vaccines. To bridge the gap between CHMI and endemic set-
tings, strain specific CHMI have been developed for Pf.
Isaie Reuling (Radboud University Medical Center, The Nether-
lands), Ilin Chuang (Armed Forces Research Institute of Medical
Sciences, Thailand), Steve Hoffman (Sanaria Inc.) discussed the
need for an increasing number of Pf strains for CHMI. Three addi-
tional strains are currently being characterised in CHMI: 7G8 from
Brazil, NF135.C10 from Cambodia and NF166.C8 from Guinea
[16,17]. Possibilities to mix strains or infect with several small
doses of different strains at short intervals was debated with some
reservations as interpretation of the trial particularly when infec-
tivity of strains differ becomes highly complicated.
Considerable efforts have also been undertaken to develop a
Plasmodium vivax (Pv) challenge model, facing major logistical
challenges as the Pv parasite cannot be continuously cultured
in vitro [18]. Socrates Herrera (Caucaseco Scientific Research Cen-
ter, Colombia) showed the advances which have been made to
establish a Pv controlled infection model. Although Pv strains are
always directly obtained from the field, natural Pv isolate hetero-
geneity and mosquito species diversity does not affect endpoint
readout, so that Pv CHMI does not need further standardisation
[19,20]. Because Pv produces gametocytes very early in infection,
the spread of the challenge strain through the bites of naturally
occuring Anopheles mosquitoes has been a concern. However, in
the initial phase these gametocytes do not seem to be able to infect
mosquitoes. The Pv model has been taken further to, very success-
fully, test efficacy of radiation-attenuated Pv sporozoites adminis-
tered by mosquito bite [21].4. CHMI in endemic areas: mapping pre-exposure and building
the capacity
The technique of direct intravenous inoculation of cryopre-
served sporozoites has expanded the field of CHMI into endemic
areas [7,8]. CHMI are now being performed in endemic areas in
Africa to test the efficacy of novel vaccines (NCT02132299,
NCT02627456). In these trials, a small group of volunteers which
may be selected based on their geographical location or pre-
exposure to malaria, is randomized, immunized and subsequently
infected by intravenous inoculation of Pf sporozoites. African CHMI
require modification of the trial endpoints because Africans, unlike
non-endemic populations, can harbour malaria parasites without
clinical symptoms and are able to (partially) clear parasites with-
out treatment [7,8]. As such, the endpoint of African CHMI can
be based on microscopy and/or clinical malaria rather than detec-
tion of any parasite by PCR.
Past exposure to malaria parasites, but also parasitic helminths
or other co-infections are known to affect immunological
responses to infection and vaccination [22]. Seif Shekalage (Ifakara
Health Institute, Tanzania), Issaka Sagara (Malaria Research and
Training Center, University of Bamako, Mali), Bernhards Ogutu
(Kenya Medical Research Institute, Kenya), Ally Olotu (Equatorial
Guinea Malaria Vaccine Initiative, Equatorial Guinea) and Ulysse
Ateba Ngoa (Centre de Recherches Médicales de Lambaréne,
Gabon) represented the African CHMI community and shared their
experiences of their trials. They emphasized hurdles faced when
performing CHMI in the field. First of all, they are facing the need
to map previous exposure to malaria parasites and other
pathogens including the presence of co-infections as parameters
in the CHMI equation [8,23]. Whereas they agree to provide anti-
malarial treatment for parasitemic subjects prior to immunisation
or infection, this should potentially be expanded to also include
treatment for concurrent helminth infections [24]. As yet, there
is no consensus on the type and number of parasites that should
be tested and treated before the trial. The preferred timing and
treatment regimen for malaria was discussed, but head-to-head
comparisons are lacking and investigators are often bound by local
malaria treatment customs. Drugs most commonly provided to
clear infections before CHMI were artesunate monotherapy, arte-
misinin combination therapy or clindamycin. Paramount to the
choice of drug is the mechanism of action and the drug’s half-
life. In addition, it is yet unclear how to best characterise individual
pre-exposure to Pf. In order to shed light on co-infections and their
role in modulating immune responses to subsequent infections or
vaccinations, full characterisation of the co-infection status and an
assessment of the serological malaria status is needed before inclu-
sion. As a consequence of the heterogeneity in trial volunteers,
African CHMI may require increased sample size particularly in
sites where pre-exposure and co-infection induces variation in
the clinical trial endpoints. For example, pre-exposure to malaria
may decrease susceptibility to CHMI for individual volunteers
regardless of the trial intervention and co-infection may influence
immune status and subsequent vaccine responses.
Most importantly, the African researchers emphasized the
importance of training of personnel at endemic sites, including
capacity building regarding ethics committees to review such trials
as well as clinical and technological capabilities.
5. CHMI for different life cycle stages
In addition to the most frequently used CHMI with the use of
sporozoites, the model has also been adapted for evaluation of
blood stage and gametocytocidal drugs or vaccines [25,26]. Ben-
jamin Mordmüller (University of Tübingen, Germany), Jim Kublin
(Seattle Malaria Clinical Trials Center, USA), Simon Draper (Univer-
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Switzerland) and James McCarthy (University of Queensland, Aus-
tralia) shared their experiences with CHMI for drug and vaccine
development as well as its potential to assess transmission block-
ing interventions. The use of blood stage challenge to assess the
parasite multiplication rates was discussed by Simon Draper [26].
Medicines for Malaria Venture, in collaboration with the
Universities of Queensland (blood stage activity) and Tübingen
(liver stage activity) have very successfully set up a pipeline
whereby drugs are selected based on data from PK/PD as well as
the CHMI data [27]. In drug CHMI, volunteers are treated with
the experimental drugs until they are cured [28]. In addition, a
clinical symptom score was developed which allowed for extended
observation of participants. It was found that the obtained parasite
reduction rates were comparable between CHMI and field studies.
James McCarthy also alluded to a newly developed model to
assess interventions targeting gametocyte by follow up of CHMI par-
ticipants after treatment with piperaquine to clear the asexual para-
sites [25]. Considerable efforts to improve this model are currently
ongoing. The use of Pv asexual blood stage parasites for CHMI is
another interesting approach, since it eliminates the risk of relapse.6. CHMI for advanced product testing/development
Now that CHMI can be performed with heterologous strains in
endemic settings, CHMI trials may cover a large part of phase 2
clinical development. The question arises whether CHMI should
be used to also provide phase 3 clinical data and eventually replace
field trials, as was recently done for the FDA approved Vaxchora, a
cholera travellers vaccine [29]. Steve Hoffman (Sanaria Inc.), Adrian
Hill (Oxford University, UK), Leo Visser (Leiden University Medical
Center, The Netherlands) weighed the advantages of fast and pos-
sibly cheaper testing with the use of CHMI against the benefits of
natural infections. Because speed and costs are paramount in clin-
ical product development, the availability of well-equipped, effi-
cient, highly endemic sites is essential. Unfortunately, these sites
may be limited in their capacity, restricting the trial design and
timelines. In addition, there are limitations with regards to phase
3 trials for travellers. For example, a proper phase 3 evaluation in
which malaria prophylaxis is compared with a novel intervention
under a non-inferiority hypothesis is logistically not possible. In
such cases, data from endemic areas, safety data from travellers
and non-endemic heterologous CHMI will need to be compiled to
provide sufficient evidence.7. Immunology in CHMI
CHMI trials can open a gateway to the basic mechanism behind
antimalarial immune responses and the immune correlates of pro-
tection against malaria. Antibodies obtained from immunized vol-
unteers can be tested for their invasion inhibiting capacity in vitro,
but also in humanized mouse models [30,31]. Increasing numbers
of cells are obtained from volunteers during and after CHMI to
identify possible crucial effector cells. Phil Felgner (University of
California, USA), Bob Seder (National Institute of Allergy and Infec-
tious Diseases NIH, USA), Carlota Dobaño (Barcelona Center for
International Health Research, Spain), Claudia Daubenberger
(Swiss Tropical and Public Health Institute, Switzerland), Sanne
de Jong (Leiden University Medical Center, The Netherlands), Chris
Ockenhouse (PATH Malaria Vaccine Initiative, USA) and Ken Stuart
(Center for Infectious Disease Research Seattle, USA) presented
their recent advances in dissecting the immunological responses
following CHMI. Phil Felgner highlighted the developments in pro-
tein array technologies which have provided unprecedented infor-
mation on the antibody profile [32–34].Bob Seder stated that the Achilles’ heel of malaria immunity is
probably in the liver and questioned whether PBMCs accurately
reflect liver-specific immune responses [35]. He made a strong plea
for investment into a peptide library of the Pf genome to identify
dominant antigens. Chris Ockenhouse supported a comprehensive
approach, but highlighted that data from antibody assays, PBMCs,
RNA seq and stimulation assays should be combined in an attempt
to tackle antigenic heterogeneity. Claudia Daubenberger stressed
the need to investigate innate immune responses at baseline to dis-
sect the heterogeneity of responses in African populations but also
cutting-edge B-cell cloning technology that might help the malaria
field in the same way that it has helped to identify broadly neutral-
izing antibodies for viral infections [36]. Carlota Dobaño shared her
work on the cellular immune response in PBMCs of several CHMI
and vaccine trials showing that antigen-specific Th2 responses can
be correlated to the risk of malaria, emphasizing the need to expand
the breadth of immune-profiling in African populations exposed to
other environmental factors and thus include Th2 and Treg
biomarkers (unpublished data). These arguments were further sup-
ported by data from Sanne de Jong (on behalf of Maria Yazdan-
bakhsh), who showed the strikingly different immune fingerprint
of Africans and Europeans before and after CHMI with the use of
mass cytometry technology (unpublished data). Ken Stuart pre-
sented work on CHMI studies where responses to radiation-
attenuated parasites were tested. The flow cytometry, cytokine
and RNA-Seq data have been generated and are being integrated
and analysed. The studies showed different transcriptional patterns
when one considered protected and non-protected subjects. In addi-
tion, a possible role for Mucosal Associated Invariant T-cells in
response to malaria infection was put forward. Stuart emphasized
that a network modelling the immune responses will be necessary
for fully understanding responses to infections and successful vacci-
nes where controlled human infections can play an important role.8. Challenges and perspectives
Controlled human malaria infection, at the forefront of con-
trolled human infection models, is a multifaceted dynamic model
which is adapted to suit specific research questions related to vac-
cine or drug development. As the field of malaria research is still
struggling with many essential questions, such as the correlates
of protection, mechanisms of protection, cross-strain protection
and heterogeneity of responses in African populations, the use of
the CHMI model has expanded to endemic areas and a portfolio
of different strains, species and lifecycle stages are being built.
Omics approaches will facilitate the further dissection of these
important parameters if the right questions are asked. Integration
of immunological parameters such as antibody, RNA seq, mass
cytometry and other novel tools to obtain an integrated signature
of immunity, will remain a challenge. Collaboration between
research centres performing these demanding trials will prove to
be essential to draw meaningful conclusions from big-data
approaches. In addition, an increasing heterogeneity in trial design
complicates data interpretation and pooling but the efforts of put-
ting data together are essential to maximize the scientific benefit.9. Recommendations
The expansion of CHMI trials into endemic areas was perceived
as one of the major advances for the field of malaria immunology,
drug and vaccine development. Although CHMI in endemic areas
adds to the complexity of the model, it is essential for product
development and provides unprecedented opportunities for
understanding malaria immunology. CHMI shifts the risk curve of
clinical development, decreasing the chances of failure at later
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2 field trials and acts as a gatekeeper before moving into field effi-
cacy trials. Although field efficacy should always be targeted,
whenever possible the need and size of phase 2 trials may decrease
if they add to previously acquired endemic CHMI data. In order to
keep up with the high standard of care to safeguard volunteer’s
safety there is a clear need to establish an international network
of CHMI researchers to allow for real-time sharing of adverse
events and facilitate capacity building at trial sites including ethi-
cal boards. Taking into account the already existing heterogeneity
in trial design, investigators recommended not to stretch the
model initially into mixing strains or repeated dosing as this will
lead to an unduly increase of trial complexity, but rather test pro-
tection against each strain separately first before further combined
strains CHMI can be considered. Nonetheless, the already existing
diversity of models such as the blood stage CHMI or the Pv CHMI,
were considered valuable tools for the drug and vaccine develop-
ment pipeline.
Continuing the discussion on CHMI safety, design and harmon-
isation is paramount to provide a framework for the ethical and
scientific acceptance of the CHMI trials and secure the ongoing
use of this highly valuable tool.
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